Jump to content

Atomoxetine

From Pharmacopedia
Revision as of 18:42, 15 May 2026 by MDElliottMD (talk | contribs) (Comprehensive categorization: +Norepinephrine Reuptake Inhibitors (NRIs), Stimulants & Wake-Promoting Agents)
NRI, ADHD medicine
Atomoxetine
Strattera

Experience

👥 No personal reports yet
No clinical reports yet

Log in to add your own experience.

Problems

No problems yet. Be the first to suggest one.

+ Add a problem

Titration strategies

No titration strategies yet. Be the first to suggest one.

+ Add a titration strategy

Effects

No effects listed yet. Be the first to suggest one.

+ Add an effect

Interactions

Pharmacogenomic + mechanism interactions4 edges
Pharmacogenomic guideline recommendationsCPIC and Dutch Pharmacogenetics Working Group clinical guidelines
Phenotype:CYP2D6 poor metabolizer dose increase CPIC A 75 / 100
CPIC rec 8093480 [Strong]: Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]
Phenotype:CYP2D6 ultrarapid metabolizer dose increase CPIC A 50 / 100
CPIC rec 8093460 [Moderate]: Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]
Phenotype:CYP2D6 normal metabolizer dose increase CPIC A 50 / 100
CPIC rec 8093471 [Moderate]: Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]
Phenotype:CYP2D6 intermediate metabolizer dose increase CPIC A 50 / 100
CPIC rec 8093476 [Moderate]: Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. CPIC pair-level A (CYP2D6 and Atomoxetine) [PMID 30801677]

Patient experience

No patient-experience reports yet.

Relevant anecdote

No anecdotes yet. Share a relevant one.

+ Add an anecdote

Relevant Literature

No literature entries yet.

Log in to submit relevant literature.

Summary
Classes
NRI, ADHD medicine
Common uses
Pharmacy
Pharmacology
Purported mechanism
Selective norepinephrine reuptake inhibitor